Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37[1] designed for the treatment of cancer.[2]

Otlertuzumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetCD37
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC4660H7136N1246O1452S30
Molar mass104809.42 g·mol−1

This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL)[3]

References

edit
  1. ^ Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S (December 2018). "Anti-CD37 targeted immunotherapy of B-Cell malignancies". Biotechnology Letters. 40 (11–12): 1459–1466. doi:10.1007/s10529-018-2612-6. PMID 30293139. S2CID 52925605.
  2. ^ "Otlertuzumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
  3. ^ "Otlertuzumab". ClinicalTrails.gov. U.S. National Library of Medicine.